{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T18:18:15Z","timestamp":1648664295465},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2009,5,6]],"date-time":"2009-05-06T00:00:00Z","timestamp":1241568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s00277-009-0734-6","type":"journal-article","created":{"date-parts":[[2009,5,5]],"date-time":"2009-05-05T09:35:59Z","timestamp":1241516159000},"page":"1107-1112","source":"Crossref","is-referenced-by-count":3,"title":["Intermediate dose gemcitabine\u2013cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting\u2014a new standard of care in relapsed or refractory Hodgkin lymphoma?"],"prefix":"10.1007","volume":"88","author":[{"given":"T.","family":"Todd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Raj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Camilleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Stafford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bulusu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Follows","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,6]]},"reference":[{"key":"734_CR1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","volume":"21","author":"DB Duggan","year":"2003","unstructured":"Duggan DB, Petroni GR, Johnson JL et al (2003) Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin\u2019s disease: report of an intergroup trial. J Clin Oncol 21:607\u2013614. doi: 10.1200\/JCO.2003.12.086","journal-title":"J Clin Oncol"},{"key":"734_CR2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJM199302253280808","volume":"328","author":"VT DeVita Jr","year":"1993","unstructured":"DeVita VT Jr, Hubbard SM (1993) Hodgkin\u2019s disease. N Engl J Med 328:560\u2013565. doi: 10.1056\/NEJM199302253280808","journal-title":"N Engl J Med"},{"key":"734_CR3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1023\/A:1026454831340","volume":"10","author":"J Aparicio","year":"1999","unstructured":"Aparicio J, Segura A, Garcera S et al (1999) ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 10:593\u2013595. doi: 10.1023\/A:1026454831340","journal-title":"Ann Oncol"},{"key":"734_CR4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.bmt.1705792","volume":"40","author":"S Akhtar","year":"2007","unstructured":"Akhtar S, El Weshi A, Abdelsalam M et al (2007) Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients. Bone Marrow Transplant 40:651\u2013658. doi: 10.1038\/sj.bmt.1705792","journal-title":"Bone Marrow Transplant"},{"key":"734_CR5","doi-asserted-by":"crossref","unstructured":"Brice P (2008) Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol \u25aa\u25aa\u25aa:3\u201313. doi: 10.1111\/j.1365-2141.2008.06998.x","DOI":"10.1111\/j.1365-2141.2008.06998.x"},{"key":"734_CR6","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2000.18.13.2615","volume":"18","author":"A Santoro","year":"2000","unstructured":"Santoro A, Bredenfeld L, Devizzi L et al (2000) Gemcitabine in the treatment of refractory Hodgkin\u2019s disease: results of a multicentre phase II study. J Clin Oncol 18:2615\u20132619","journal-title":"J Clin Oncol"},{"key":"734_CR7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","volume":"92","author":"A Santoro","year":"2007","unstructured":"Santoro A, Magagnoli M, Spina A et al (2007) Ifosfamide, gemcitabine and Vinorelbine: A new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma. Haematologica 92:35\u201341. doi: 10.3324\/haematol.10661","journal-title":"Haematologica"},{"key":"734_CR8","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdg496","volume":"14","author":"T Baetz","year":"2003","unstructured":"Baetz T, Belch A, Couban S et al (2003) Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin\u2019s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 14:1762\u20131767. doi: 10.1093\/annonc\/mdg496","journal-title":"Ann Oncol"},{"key":"734_CR9","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1046\/j.1365-2141.2003.04226.x","volume":"120","author":"I Chau","year":"2003","unstructured":"Chau I, Harries M, Cunningham D et al (2003) Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. Br J Haem 120:970\u2013977. doi: 10.1046\/j.1365-2141.2003.04226.x","journal-title":"Br J Haem"},{"issue":"14S","key":"734_CR10","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1200\/jco.2004.22.14_suppl.6589","volume":"22","author":"J Waters","year":"2004","unstructured":"Waters J, Chau I, Norman AR et al (2004) Gemcitabine (GEM), cisplatin (P) and methylprednisolone: A salvage regimen in relapsed Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 22(14S):6589 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)","journal-title":"J Clin Oncol"},{"key":"734_CR11","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/sj.bjc.6602514","volume":"92","author":"M Ng","year":"2005","unstructured":"Ng M, Waters J, Cunningham D et al (2005) Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 92:1352\u20131357","journal-title":"Br J Cancer"},{"key":"734_CR12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.bmt.1704483","volume":"33","author":"U Popat","year":"2004","unstructured":"Popat U, Hosing C, Saliba RM et al (2004) Prognostic factors for disease progression after HDT and ASCT for recurrent or refractory Hodgkin lymphoma. Bone Marrow Transplant 33:1015\u20131023. doi: 10.1038\/sj.bmt.1704483","journal-title":"Bone Marrow Transplant"},{"key":"734_CR13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586. doi: 10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"key":"734_CR14","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/JCO.1994.12.3.580","volume":"12","author":"MG Pfreundschuh","year":"1994","unstructured":"Pfreundschuh MG, Rueffer U, Lathan B et al (1994) Dexa-BEAM in patients with Hodgkin\u2019s disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin\u2019s Disease Study Group. J Clin Oncol 12:580\u2013586","journal-title":"J Clin Oncol"},{"key":"734_CR15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2141.2001.02714.x","volume":"113","author":"A Martin","year":"2001","unstructured":"Martin A, Fernandez-Jimenez MC, Caballero MD et al (2001) Long-term follow up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin\u2019s disease. Br J Haematol 113:161\u2013171. doi: 10.1046\/j.1365-2141.2001.02714.x","journal-title":"Br J Haematol"},{"key":"734_CR16","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1182\/blood.V93.11.3632","volume":"93","author":"J Rodriguez","year":"1999","unstructured":"Rodriguez J, Rodriguez MA, Fayad L et al (1999) ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin\u2019s disease. Blood 93:3632\u20133636","journal-title":"Blood"},{"key":"734_CR17","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/sj.bmt.1701202","volume":"21","author":"V Ribrag","year":"1998","unstructured":"Ribrag V, Nasr F, Bouhris JH et al (1998) VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin\u2019s disease. Bone Marrow Transplant 21:969\u2013974. doi: 10.1038\/sj.bmt.1701202","journal-title":"Bone Marrow Transplant"},{"key":"734_CR18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","volume":"97","author":"CH Moskowitz","year":"2001","unstructured":"Moskowitz CH, Nimer SD, Zelenetz AD et al (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97:616\u2013623. doi: 10.1182\/blood.V97.3.616","journal-title":"Blood"},{"key":"734_CR19","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","volume":"13","author":"A Josting","year":"2002","unstructured":"Josting A, Rudolph C, Reiser M et al (2002) Time-intensified dexamethasone\/ cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease. Ann Oncol 13:1628\u20131635. doi: 10.1093\/annonc\/mdf221","journal-title":"Ann Oncol"},{"key":"734_CR20","first-page":"494","volume":"86","author":"MA Canales","year":"2001","unstructured":"Canales MA, Fernandez-Jimenez MC, Martin A et al (2001) Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Haematologica 86:494\u2013498","journal-title":"Haematologica"},{"key":"734_CR21","volume-title":"Beccles","author":"Joint Formulary Committee British National Formulary","year":"2008","unstructured":"Joint Formulary Committee British National Formulary (2008) Beccles. Pharmaceutical Press, London"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-009-0734-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-009-0734-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-009-0734-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T23:14:37Z","timestamp":1589757277000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-009-0734-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,6]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["734"],"URL":"https:\/\/doi.org\/10.1007\/s00277-009-0734-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,6]]}}}